A comprehensive view of AbbVie Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AbbVie reports FDA has requested further information on subcutaneous pump used in its ABBV-951 combination therapy to treat Parkinson’s disease; treatment uses foscarbidopa and foslevodopa along with pump device
Published: March 23, 2023 by FiercePharma
Amgen Launches Amjevita, a biosimilar to AbbVie's Humira adalimumab, in US to treat seven inflammatory diseases including moderate-to-severe rheumatoid arthritis in adults; Amjevita’s wholesale acquisition cost is 55% below current Humira list price
Published: February 02, 2023 by Mondaq Business Briefing
AbbVie, Eli Lilly leave UK’s voluntary medicines pricing agreement, will operate under the Statutory Scheme for Branded Medicines; statutory scheme historically has a higher repayment rate, with a further rise currently under consideration
Published: January 16, 2023 by PharmaTimes
AbbVie partners with Anima Biotech to develop mRNA drugs focused on three targets in oncology, immunology; AbbVie to have exclusive rights to license, develop, commercialize the drugs in deal worth up to US$540.0M
Published: January 11, 2023 by SeeNews Pharmaceuticals
AbbVie partners with clinical-stage biopharma Immunome to use Immunome’s Discovery Engine to identify up to 10 novel target-antibody pairs arising from three specified tumor types; Immunome to receive US$30.0M upfront payment
Published: January 06, 2023 by Business Wire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count